CTLA4 and colitis: Similar to the non-adjuvant group, in the single-agent anti-CTLA4, colitis (30.8%) and hypophysitis (30.8%) were frequent treatment-related toxicities that were associated with severe, grade 3–4 adverse events in 23.1% and 15.4% of the cases, respectively.